{"_links":{"self":{"href":"/api/v2/datasets/doi:10.5061%2Fdryad.4mw6m906b/versions"},"first":{"href":"/api/v2/datasets/doi:10.5061%2Fdryad.4mw6m906b/versions"},"last":{"href":"/api/v2/datasets/doi:10.5061%2Fdryad.4mw6m906b/versions?page=1"}},"count":2,"total":2,"_embedded":{"stash:versions":[{"_links":{"self":{"href":"/api/v2/versions/37370"},"stash:dataset":{"href":"/api/v2/datasets/doi%3A10.5061%2Fdryad.4mw6m906b"},"stash:files":{"href":"/api/v2/versions/37370/files"},"stash:download":{"href":"/api/v2/versions/37370/download"},"curies":[{"name":"stash","href":"https://github.com/datadryad/dryad-app/blob/main/documentation/apis/link_relations.md#{rel}","templated":"true"}]},"title":"Data from: The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular Degeneration","authors":[{"firstName":"Katrin","lastName":"Fasler","email":"katrin.fasler@usz.ch","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0002-0348-961X","order":null},{"firstName":"Dun Jack","lastName":"Fu","email":"d.fu@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0003-2852-6912","order":null},{"firstName":"Gabriella","lastName":"Moraes","email":"gabriella.nogueira@gmail.com","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0003-3358-5861","order":null},{"firstName":"Siegfried K","lastName":"Wagner","email":"siegfried.wagner1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Eesha","lastName":"Gokhale","email":"e.gokhale@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Karsten U","lastName":"Kortuem","email":"karsten.kortuem@med.uni-muenchen.de","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0001-9442-0708","order":null},{"firstName":"Reena","lastName":"Chopra","email":"reena.chopra1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Livia","lastName":"Faes","email":"l.faes@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Gabriella","lastName":"Preston","email":"e.preston@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Nikolas","lastName":"Pontikos","email":"n.pontikos@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Praveen J","lastName":"Patel","email":"praveen.patel1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Adnan","lastName":"Tufail","email":"adnan.tufail@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Aaron Y","lastName":"Lee","email":"aaronylee@gmail.com","affiliation":"University of Washington","affiliationROR":"https://ror.org/00cvxb145","affiliations":[{"name":"University of Washington","ror_id":"https://ror.org/00cvxb145"}],"orcid":null,"order":null},{"firstName":"Konstantinos","lastName":"Balaskas","email":"k.balaskas@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Pearse A","lastName":"Keane","email":"pearse.keane1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0002-9239-745X","order":null}],"abstract":"\u003cp\u003e\u003cb\u003eBackground/Aims:\u003c/b\u003e Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on ‘fellow eyes’’ have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement.\u003c/p\u003e\r\n\r\n\u003cp\u003e\u003cb\u003eMethods:\u003c/b\u003e Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients /120,286 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 807 nonsequential, and 3410 unilateral eyes.\u003c/p\u003e\r\n\r\n\u003cp\u003e\u003cb\u003eResults: \u003c/b\u003eMean VA (Early Treatment Diabetic Retinopathy Study letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over two years lower (0.37±14), and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at two years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27-147) weeks.\u003c/p\u003e\r\n\r\n\u003cp\u003e\u003cb\u003eConclusion:\u003c/b\u003e This report shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.\u003c/p\u003e\r\n","versionNumber":5,"versionStatus":"submitted","curationStatus":"Published","versionChanges":"metadata_changed","publicationDate":"2019-10-01","lastModificationDate":"2019-10-01","visibility":"public","sharingLink":"http://datadryad.org/dataset/doi:10.5061/dryad.4mw6m906b"},{"_links":{"self":{"href":"/api/v2/versions/96875"},"stash:dataset":{"href":"/api/v2/datasets/doi%3A10.5061%2Fdryad.4mw6m906b"},"stash:files":{"href":"/api/v2/versions/96875/files"},"stash:download":{"href":"/api/v2/versions/96875/download"},"curies":[{"name":"stash","href":"https://github.com/datadryad/dryad-app/blob/main/documentation/apis/link_relations.md#{rel}","templated":"true"}]},"title":"Data from: The Moorfields AMD database report 2 - fellow eye involvement with neovascular age-related macular degeneration","authors":[{"firstName":"Katrin","lastName":"Fasler","email":"katrin.fasler@usz.ch","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0002-0348-961X","order":null},{"firstName":"Dun Jack","lastName":"Fu","email":"d.fu@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0003-2852-6912","order":null},{"firstName":"Gabriella","lastName":"Moraes","email":"gabriella.nogueira@gmail.com","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0003-3358-5861","order":null},{"firstName":"Siegfried K","lastName":"Wagner","email":"siegfried.wagner1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Eesha","lastName":"Gokhale","email":"e.gokhale@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Karsten U","lastName":"Kortuem","email":"karsten.kortuem@med.uni-muenchen.de","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0001-9442-0708","order":null},{"firstName":"Reena","lastName":"Chopra","email":"reena.chopra1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Livia","lastName":"Faes","email":"l.faes@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Gabriella","lastName":"Preston","email":"e.preston@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Nikolas","lastName":"Pontikos","email":"n.pontikos@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Praveen J","lastName":"Patel","email":"praveen.patel1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Adnan","lastName":"Tufail","email":"adnan.tufail@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Aaron Y","lastName":"Lee","email":"aaronylee@gmail.com","affiliation":"University of Washington","affiliationROR":"https://ror.org/00cvxb145","affiliations":[{"name":"University of Washington","ror_id":"https://ror.org/00cvxb145"}],"orcid":null,"order":null},{"firstName":"Konstantinos","lastName":"Balaskas","email":"k.balaskas@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":null,"order":null},{"firstName":"Pearse A","lastName":"Keane","email":"pearse.keane1@nhs.net","affiliation":"Moorfields Eye Hospital NHS Foundation Trust","affiliationROR":"https://ror.org/03zaddr67","affiliations":[{"name":"Moorfields Eye Hospital NHS Foundation Trust","ror_id":"https://ror.org/03zaddr67"}],"orcid":"0000-0002-9239-745X","order":null}],"abstract":"\u003cp\u003e\u003cb\u003eBackground/Aims:\u003c/b\u003e Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on ‘fellow eyes’’ have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement.\u003c/p\u003e\r\n\r\n\u003cp\u003e\u003cb\u003eMethods:\u003c/b\u003e Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients /120,286 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 807 nonsequential, and 3410 unilateral eyes.\u003c/p\u003e\r\n\r\n\u003cp\u003e\u003cb\u003eResults: \u003c/b\u003eMean VA (Early Treatment Diabetic Retinopathy Study letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over two years lower (0.37±14), and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at two years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27-147) weeks.\u003c/p\u003e\r\n\r\n\u003cp\u003e\u003cb\u003eConclusion:\u003c/b\u003e This report shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.\u003c/p\u003e\r\n","relatedWorks":[{"relationship":"primary_article","identifierType":"DOI","identifier":"https://doi.org/10.1136/bjophthalmol-2019-314446"}],"versionNumber":7,"versionStatus":"submitted","curationStatus":"Published","versionChanges":"metadata_changed","publicationDate":"2020-12-18","lastModificationDate":"2020-12-18","visibility":"public","sharingLink":"http://datadryad.org/dataset/doi:10.5061/dryad.4mw6m906b"}]}}